Inulin-type fructans supplementation improves glycemic control for the prediabetes and type 2 diabetes populations: a GRADE-assessed systematic review and dose-response meta-analysis of 33 randomized controlled trials
Wang L, Yang H, Huang H, Zhang C, Zuo HX, Xu P, Niu YM, Wu SS
Published in Journal of Translational Medicine
Methodology
GRADE-assessed systematic review and dose-response meta-analysis of 33 randomised controlled trials of inulin-type fructans in prediabetes and type 2 diabetes
Key Findings
Inulin-type fructans significantly reduced fasting glucose, HbA1c, fasting insulin and HOMA-IR, with benefit most evident at doses around 10 g daily for at least 6 weeks.
Conclusions
Inulin-type fructans provide modest but consistent glycaemic improvement in dysglycaemic populations.
Limitations
Moderate heterogeneity; GRADE certainty low to moderate for several outcomes.
Supplements Studied
Inulin-type fructans significantly reduced fasting glucose, HbA1c, fasting insulin and HOMA-IR, with benefit most evident at doses around 10 g daily for at least 6 weeks.
Outcomes Measured
Inulin-type fructans significantly reduced fasting glucose, HbA1c, fasting insulin and HOMA-IR, with benefit most evident at doses around 10 g daily for at least 6 weeks.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.